Proangiogenic properties of human myeloma cells: production of angiopoietin-1 and its potential relationship to myeloma-induced angiogenesis
Author:
Giuliani Nicola1, Colla Simona1, Lazzaretti Mirca1, Sala Roberto1, Roti Giovanni1, Mancini Cristina1, Bonomini Sabrina1, Lunghi Paolo1, Hojden Magda1, Genestreti Giovenzio1, Svaldi Mirija1, Coser Paolo1, Fattori Pier Paolo1, Sammarelli Gabriella1, Gazzola Gian Carlo1, Bataille Regis1, Almici Camillo1, Caramatti Cecilia1, Mangoni Lina1, Rizzoli Vittorio1
Affiliation:
1. From the Hematology and Bone Marrow Transplantation (BMT) Unit and the Departments of Pathology and Experimental Medicine, Institute of Medical Pathology, University of Parma; the Division of Oncohematology, Ospedale di Rimini, Rimini; the Department of Hematology, Ospedale Regionale, Bolzano; the Department of Hematology, Spedali Civili, Brescia, Italy; and INSERM U463, Insitut de Biologie, Nantes, France
Abstract
AbstractPatients with multiple myeloma (MM) have increased bone marrow (BM) angiogenesis; however, the proangiogenic properties of myeloma cells and the mechanisms of MM-induced angiogenesis are not completely clarified. The angiopoietin system has been identified as critical in the regulation of vessel formation. In this study we have demonstrated that myeloma cells express several proangiogenic factors, and, in particular, we found that angiopoietin-1 (Ang-1), but not its antagonist Ang-2, was expressed by several human myeloma cell lines (HMCLs) at the mRNA and the protein levels. In a transwell coculture system, we observed that myeloma cells up-regulated the Ang-1 receptor Tie2 in human BM endothelial cells. Moreover, in an experimental model of angiogenesis, the conditioned medium of HMCLs significantly stimulated vessel formation compared with control or vascular endothelial growth factor (VEGF) treatment. The presence of anti-Tie2 blocking antibody completely blunted the proangiogenic effect of XG-6. Finally, our in vitro results were supported by the in vivo finding of Ang-1, but not Ang-2, mRNA and protein expression in purified MM cells obtained from approximately 47% of patients and by high BM angiogenesis in patients with MM positive for Ang-1, suggesting that the angiopoietin system could be involved, at least in part, in MM-induced angiogenesis.
Publisher
American Society of Hematology
Subject
Cell Biology,Hematology,Immunology,Biochemistry
Reference41 articles.
1. Bataille R, Harousseau J-L. Multiple myeloma. N Engl J Med.1997;336: 1657-1664. 2. Hideshima T, Chauhan D, Podar K, Schlossman R-L, Richardson P, Anderson K-C. Novel therapies targeting the myeloma cell and its bone marrow microenvironment. Semin Oncol.2001;28: 607-612. 3. Rajkumar S-V, Mesa R-A, Fonseca R, et al. Bone marrow angiogenesis in 400 patients with monoclonal gammopathy of undetermined significance, multiple myeloma, and primary amyloidosis. Clin Cancer Res.2002;8: 2210-2216. 4. Vacca A, Ribatti D, Presta M, et al. Bone marrow neovascularization, plasma cell angiogenic potential, and matrix metalloproteinase-2 secretion parallel progression of human multiple myeloma. Blood. 1999;93: 3064-3073. 5. Vacca A, Ribatti D, Roccaro A-M, Frigeri A, Dammacco F. Bone marrow angiogenesis in patients with active multiple myeloma. Semin Oncol.2001;28: 543-550.
Cited by
98 articles.
订阅此论文施引文献
订阅此论文施引文献,注册后可以免费订阅5篇论文的施引文献,订阅后可以查看论文全部施引文献
|
|